clinical trial · NCT05160584
A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma
Janssen Pharmaceutica N.V., Belgium·—·recruiting·n = 300
Relapsed/Refractory Multiple MyelomaNo intervention
brief summary
The purpose of this study is to assess in real-life clinical practice, over a 24-month period, the effectiveness and safety and patient-reported outcomes (PROs) associated with standard of care (SOC) antimyeloma treatments in participants with previously treated relapsed and/or refractory multiple myeloma.
started
Nov 18, 2021
primary completion
Apr 30, 2028
completion
Jul 31, 2028
last updated
Apr 13, 2026
official title
A Prospective, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol